Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 324

1.

Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro.

Liu MY, Wang WZ, Liao FF, Wu QQ, Lin XH, Chen YH, Cheng L, Jin XB, Zhu JY.

Cell Biol Int. 2017 Jan;41(1):16-23. doi: 10.1002/cbin.10686. Epub 2016 Nov 16.

PMID:
27677634
2.

Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.

Reddiconto G, Toto C, Palamà I, De Leo S, de Luca E, De Matteis S, Dini L, Passerini CG, Di Renzo N, Maffia M, Coluccia AM.

Blood. 2012 Mar 8;119(10):2335-45. doi: 10.1182/blood-2011-06-361261. Epub 2012 Jan 18.

3.

Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.

Lin H, Chen M, Rothe K, Lorenzi MV, Woolfson A, Jiang X.

Oncotarget. 2014 Sep 30;5(18):8637-50.

4.

Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.

Salati S, Salvestrini V, Carretta C, Genovese E, Rontauroli S, Zini R, Rossi C, Ruberti S, Bianchi E, Barbieri G, Curti A, Castagnetti F, Gugliotta G, Rosti G, Bergamaschi M, Tafuri A, Tagliafico E, Lemoli R, Manfredini R.

Oncotarget. 2017 Jul 25;8(30):49451-49469. doi: 10.18632/oncotarget.17706.

5.

Silencing of miR-21 sensitizes CML CD34+ stem/progenitor cells to imatinib-induced apoptosis by blocking PI3K/AKT pathway.

Wang WZ, Pu QH, Lin XH, Liu MY, Wu LR, Wu QQ, Chen YH, Liao FF, Zhu JY, Jin XB.

Leuk Res. 2015 Oct;39(10):1117-24. doi: 10.1016/j.leukres.2015.07.008. Epub 2015 Jul 21.

PMID:
26248946
6.

Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists.

Zhao Y, Wu K, Wu Y, Melendez E, Smbatyan G, Massiello D, Kahn M.

Curr Mol Pharmacol. 2018;11(2):113-121. doi: 10.2174/1874467210666170919155739.

PMID:
28933312
7.

Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells.

Kuntz EM, Baquero P, Michie AM, Dunn K, Tardito S, Holyoake TL, Helgason GV, Gottlieb E.

Nat Med. 2017 Oct;23(10):1234-1240. doi: 10.1038/nm.4399. Epub 2017 Sep 18.

8.

Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.

Aljedai A, Buckle AM, Hiwarkar P, Syed F.

PLoS One. 2015 Apr 7;10(4):e0123016. doi: 10.1371/journal.pone.0123016. eCollection 2015.

9.

Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate.

Zhang B, Strauss AC, Chu S, Li M, Ho Y, Shiang KD, Snyder DS, Huettner CS, Shultz L, Holyoake T, Bhatia R.

Cancer Cell. 2010 May 18;17(5):427-42. doi: 10.1016/j.ccr.2010.03.011.

10.

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.

Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, Barow M, Mountford JC, Holyoake TL.

Blood. 2006 Jun 1;107(11):4532-9. Epub 2006 Feb 9.

11.

BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.

Copland M, Pellicano F, Richmond L, Allan EK, Hamilton A, Lee FY, Weinmann R, Holyoake TL.

Blood. 2008 Mar 1;111(5):2843-53. Epub 2007 Dec 21. Erratum in: Blood. 2008 May 1;111(9):4830.

12.

Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.

Carter BZ, Mak PY, Mak DH, Ruvolo VR, Schober W, McQueen T, Cortes J, Kantarjian HM, Champlin RE, Konopleva M, Andreeff M.

Oncotarget. 2015 Oct 13;6(31):30487-99. doi: 10.18632/oncotarget.5890.

13.

ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.

Airiau K, Mahon FX, Josselin M, Jeanneteau M, Turcq B, Belloc F.

Exp Hematol. 2012 May;40(5):367-78.e2. doi: 10.1016/j.exphem.2012.01.004. Epub 2012 Jan 10.

PMID:
22240609
14.

Comparative effect of imatinib and ponatinib on autophagy and miRNome in chronic myeloid leukemia.

Kayabasi C, Okcanoglu TB, Yelken BO, Asik A, Susluer SY, Avci CB, Saydam G, Gunduz C.

Gene. 2017 Dec 30;637:173-180. doi: 10.1016/j.gene.2017.09.036. Epub 2017 Sep 20.

PMID:
28942039
15.

BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.

Chu S, Holtz M, Gupta M, Bhatia R.

Blood. 2004 Apr 15;103(8):3167-74. Epub 2003 Dec 11.

16.

Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells.

Abraham SA, Hopcroft LE, Carrick E, Drotar ME, Dunn K, Williamson AJ, Korfi K, Baquero P, Park LE, Scott MT, Pellicano F, Pierce A, Copland M, Nourse C, Grimmond SM, Vetrie D, Whetton AD, Holyoake TL.

Nature. 2016 Jun 16;534(7607):341-6. doi: 10.1038/nature18288. Epub 2016 Jun 8.

17.

Antitumor Effects of Blocking Protein Neddylation in T315I-BCR-ABL Leukemia Cells and Leukemia Stem Cells.

Liu C, Nie D, Li J, Du X, Lu Y, Li Y, Zhou J, Jin Y, Pan J.

Cancer Res. 2018 Mar 15;78(6):1522-1536. doi: 10.1158/0008-5472.CAN-17-1733. Epub 2018 Jan 10.

18.

Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.

Wu L, Yu J, Chen R, Liu Y, Lou L, Wu Y, Huang L, Fan Y, Gao P, Huang M, Wu Y, Chen Y, Xu J.

Clin Cancer Res. 2015 Feb 15;21(4):833-43. doi: 10.1158/1078-0432.CCR-13-3317. Epub 2014 Dec 11.

19.

CDKIs p18(INK4c) and p57(Kip2) are involved in quiescence of CML leukemic stem cells after treatment with TKI.

Moreno-Lorenzana D, Avilés-Vazquez S, Sandoval Esquivel MA, Alvarado-Moreno A, Ortiz-Navarrete V, Torres-Martínez H, Ayala-Sánchez M, Mayani H, Chavez-Gonzalez A.

Cell Cycle. 2016 May 2;15(9):1276-87. doi: 10.1080/15384101.2016.1160976.

20.

Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.

Jin Y, Zhou J, Xu F, Jin B, Cui L, Wang Y, Du X, Li J, Li P, Ren R, Pan J.

J Clin Invest. 2016 Oct 3;126(10):3961-3980. doi: 10.1172/JCI85239. Epub 2016 Sep 19.

Supplemental Content

Support Center